Novo Nordisk’s Stock Went On A Crash Diet, And Investors Demonstrated Their Love For Oura
The Finimize Daily Brief - Un podcast de Finimize
Catégories:
Novo Nordisk’s shares slimmed way down as investors felt disappointed by its latest obesity drug trial, while Oura raised $200 million from investors – proving it’s not just celebrities and executives who adore the Finnish smart rings.Today’s stories:Novo Nordisk’s Stock Went On A Crash Diet After The Firm’s Latest Clinical TrialInvestors Demonstrated Their Love For Oura, Lifting The Smart Ring Brand’s ValuationTry Finimize Pro
